Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HALB-Halberd’s Successful Completion of Sampling Phase Marks Major Milestone for Project at Mississippi State University (MSU)
Press Release | 08/22/2023
Novel Nasal Spray for Traumatic Brain Injury Effects Poised to Demonstrate Efficacy in Patent-Pending Product
JACKSON CENTER, PA / ACCESSWIRE / August 22, 2023 / Halberd Corporation (OTC PINK:HALB) announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects. This enables MSU to proceed with its pre-clinical model to study endpoints for Halberd's groundbreaking patent-pending nasal spray's ability to mitigate the effects of traumatic brain injury (TBI). The analysis of these tissue samples can now proceed to examine and quantify the presence of certain markers related to brain damage and to assess the effectiveness of the nasal spray treatment. The nasal spray is designed to eliminate the otherwise inevitable and irreversible negative effects of TBI by directly targeting the associated antigens in cerebrospinal fluid (CSF).
Halberd's nasal spray employs a patent-pending blend of three active ingredients designed to timely address and block the excess production of certain identified inflammatory cytokines and neurotransmitters triggered by head trauma. Excess quantities of these elements are associated with irreversible brain injury. The testing at MSU will evaluate the importance of the timely application of Halberd's nasal spray within hours of a traumatic brain injury to mitigate the otherwise inevitable long-term neurodegeneraton often leading to not just TBI, but also to Alzheimer's Disease, Parkinson's Disease, Epileptic seizures, PTSD, etc.
Halberd's early treatment nasal spray product has the potential for wide acceptance by contact sports participants, first responders, trauma centers and the military. Following successful completion of these pre-clinical tests, Halberd intends to immediately seek expeditious approval of the treatment by the FDA and other regulatory bodies throughout the world to enable sale and distribution within the United States as well as other potential world markets. As previously reported, Halberd has already engaged experts for this pursuit with the FDA.
To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Mississippi State University College of Veterinary Medicine (CVM).
Mississippi State University College of Veterinary Medicine (MSU CVM) was founded in 1974 The CVM has a total of six locations and serves all 82 counties in Mississippi as well as the entire Southeastern United States. The College's main campus is in Starkville and includes the Wise Center, which houses its main teaching hospital, the Animal Health Center. The MSU CVM Department of Comparative Biomedical Sciences faculty and staff represent the basic scientific disciplines required for education of veterinarians. MSU CVM is committed to an ethical approach to treating animals with a genuine passion and drive.
good call there
waiting 2,1mil shares here.$ they r ahead of things here
4yrs here,big money here
good news this is going to be a great stock,tha tha tha
good news this is going to be a great stock,tha tha tha,buy in now or pay a lot more down the road
HALB=https://www.otcmarkets.com/stock/HALB/news/Halberd-CEO-Mid-Quarter-Update?id=402777
i am done buying,have at it good luck to u
got 3 mil today at .0006,took me awhile
how do i do a favorite
Halberd Corporation
@HalberdC
·
Mar 22
Even the extremely communicable, resistant, deadly Candida auris, is not Halberd Resistant
Halberd Corporation
@HalberdC
·
Mar 20
$HALB Halberd continues its scientific breakthrough eradication of a multiplicity of CDC- provided, antibiotic resistant bacteria and deadly Candida Auris fungi in support of their meeting with the #CDC on March 29.
#Candida #CandidaAuris #bacteria
See new Tweets
Conversation
Halberd Corporation Retweeted
The Street Reports
@ts_reports
??Potentially deadly fungal infections with Candida auris are spreading rapidly in U.S. healthcare facilities
http://bit.ly/3FG5ZEU
#CDC #pandemic #Candida #HealthNews #Infections
1:11 PM · Mar 21, 2023
·
3,134
Views
4
Retweets
3
Quotes
9
Likes
1
Bookmark
The Street Reports
@ts_reports
·
Mar 22
Replying to
@ts_reports
$HALB This under-the-radar biotech stock could have the answer to the Candida Auris Fungus Breakout!
https://topnewsguide.com/2023/02/14/halberd-corp-otc-halb-announces-breakthrough-in-candida-auris-treatment/
#Candida #CandidaAuris #bacteria #fungus #CDC #YSU
D MCG
@DMCG46883927
·
Mar 21
Replying to
@ts_reports
and
@HalberdC
And $HALB is the only Biological Research company that can handle this issue!!!
The Street Reports
@ts_reports
·
Mar 22
Replying to
@ts_reports
$HALB This under-the-radar biotech stock could have the answer to the Candida Auris Fungus Breakout!
https://topnewsguide.com/2023/02/14/halberd-corp-otc-halb-announces-breakthrough-in-candida-auris-treatment/
#Candida #CandidaAuris #bacteria #fungus #CDC #YSU
read my last post about biei and halb agreement let me know what u think is it still on?
news-
Premier Biomedical Inc. (OTC: BIEI), now known as Premier Graphene, Inc., specifies plans and timing for development of its Full Scale, Seed To Product Delivery, Graphene Initiative
(via NewsDirect)
McapMediaWire-- Premier Biomedical Inc., now known as Premier Graphene, Inc. (OTC: BIEI), funded by a public charity, qualified under Internal Revenue Code Section 501(c)(3), announces its active pursuit of and the timing of each step of its first graphene-related initiatives.
Ivan Mendez, its new CEO, and its research partners, our actively researching and preparing hemp-based graphene-enhanced formulations for a myriad of commercial and military applications. Those, initiatives, short-term and long-term, include: concrete, asphalt, 3D printing filaments, ballistic armor, UHMW polyethylene, an anti-viral / anti-bacterial multi-surface coating, fireproof polyurethane insulation expansion foams, anti-abrasion coatings, and neat & recycled PET, HDPE, and other polymers. Premier will focus on Hemp based graphene production for its sustainability and enhanced availability for a 3D heat printing machine, production line for helmets, doors and ballistic plates. It will also explore graphene implementation with regard to EV batteries, aerospace and bio-composites use.
Mr. Mendez and his team have determined that “hemp-based graphene is a game-changer, not only for technological reasons but also to assure the cost-effectiveness.” The company is working on a four-month growth cycle, three growth cycles per year, of the hemp, for stock and biomass. This will give Premier an edge over mined graphite for graphene or lithium, which are more expensive to produce and the supply chain less reliable. Since this stock and biomass is often disposed of by other growers, a virtually endless inexpensive supply of the requisite components for this endeavor our anticipated, nationwide. Hemp-based graphene has been shown to be 300 x better than lithium and stronger than regular graphene and less polluting. This enhances our position to secure carbon credits as an additional source of revenue.
This will make Premier Graphene Inc. an up-and-coming leader in the carbon capture market. Mr. Mendez highlights that “hemp requires little water, no pesticides, and is better at carbon sequestration than trees.” We are focusing on seed to point of sale production making us a vertically integrated, sustainable business model.
Premier’s next months will be focused as follows:
March- April 2023 - finish details of and parameters of agreement with Mexican-based Hemp Company, HGI industrial technologies S.A de P.I. Then commencement of the procurement of, and new equipment set up (annealing oven, high-temp printer); compound PA-6 nylon and PEEK with graphene; extrude compounded material into filaments; coupon printing and mechanical properties testing, including low-impact tests, begin follow up hemp research at IVCRC (Imperial Valley Conservation and Research Center). Begin relationship with OSU's Global Hemp Initiative, to become part of this initiative.
May-Jul 2023 - computer modeling; body scan equipment optimization; scanning of assorted body types; file conversion to printable files; assessment of mechanical properties of filament blends; preliminary ballistic testing of 10cm x 10cm plates.
Aug-Nov 2023 - Compounding and extrusion of optimized filaments; printing of assorted plates and helmets (standard sizes).
Dec- Mar 2024 - finish Mexico Hemp licensing with associates, start production and service contracts. We should begin ballistic testing; additional plate printing, as required; printing of prototype plates and helmets from 3D body scans (this could be done much sooner); amendments as required.
Apr-Jun 2024 - micro-analysis of impacted plates; chemical testing of final plates; additional plate printing and testing as needed; final project analysis and reporting.
New CEO and majority preferred stock owner CEO Ivan Mendez states “I believe we have an excellent opportunity to become a major player in strategic resources production we will be self-reliant, and be able to supply the resources for our American emerging super capacitor and EV markets, making our supply strategically placed so we won't have the same shortages problem we had during the Pandemic.”
See
https://youtu.be/loilwrfrUyU</b>
To get the latest news on the exciting developments from Premier Biomedical Inc. (OTC: BIEI), now known as Premier Graphene, Inc., subscribe by submitting to:
https://premiergrapheneinc.com/contact/</b>
maybe he got my email,$$$$$$$$$
yes i got 100000 sares today i am up o 500000
ACTION
yes i agree
its 30 million and 5% of 30 million and 5% of net money
its 30 million and 5% of 30 million and 5% of net money
Re: None
Tuesday, February 21, 2023 3:22:37 PM
Post#
76
of 76
its 30,million and 5% of net profit its all in e news @ otc,april or may of 2020,i have stock now and still buying,i own both biei and halb
its 30,million and 5% of net profit its all in e news @ otc,april or may of 2020,i have stock now and still buying,i own both biei and halb
NEWS,HALB,
Halberd Demonstrates Simultaneous Eradication of Multiple Strains of CDC Provided Antibiotic Resistant Bacteria
Killed 99.5% of a mixture of four strains of E. coli bacteria in buffer solution in vitro
JACKSON CENTER, PA / ACCESSWIRE / February 21, 2023 / Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to simultaneously eradicate multiple strains of antibiotic resistant E. coli provided by the CDC in under 10 minutes. Halberd's patented extracorporeal process and patent-pending laser eradication method in conjunction with metallic nanoparticles eliminated 99.5% of the bacteria from the sample.
Dr. Cooper, Professor, Department of Chemical and Biological Sciences at YSU stated, "Each of the 30 strains of bacteria provided by the CDC has demonstrated resistance to a wide variety of antibiotic treatments. The fact that we have been able to eliminate several, individually and in combination is a tremendous step forward. There is still much work to do to test the remaining strains of E. coli and the 30 strains of Candida auris fungus, but we are confident that our success will continue."
Dr. Sturrus, Chair and Professor, Physics, Astronomy Geology and Earth Science Department added, "Each experiment we run builds our knowledge base and uncovers new opportunities for improving the process, optimizing the experimental conditions, and bringing us another step closer to a commercial implementation of the technology."
William A. Hartman, Halberd's Chairman, President & CEO commented, "The ability to eradicate antibiotic resistant bacteria can have an astounding impact on healthcare. It could enable quicker treatments; shorter or eliminated hospitalizations; and reduced suffering and mortality. Most importantly, the eradication of dangerous antibiotic resistant bacteria and fungi takes place outside the body without the use of antibiotics.
"We plan to continue our accelerated eradication of all of the antibiotic resistant bacteria and fungi provided by the CDC and present our findings to the CDC and other government agencies at the appropriate time."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form
NEWS
Halberd Demonstrates Simultaneous Eradication of Multiple Strains of CDC Provided Antibiotic Resistant Bacteria
Killed 99.5% of a mixture of four strains of E. coli bacteria in buffer solution in vitro
JACKSON CENTER, PA / ACCESSWIRE / February 21, 2023 / Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to simultaneously eradicate multiple strains of antibiotic resistant E. coli provided by the CDC in under 10 minutes. Halberd's patented extracorporeal process and patent-pending laser eradication method in conjunction with metallic nanoparticles eliminated 99.5% of the bacteria from the sample.
Dr. Cooper, Professor, Department of Chemical and Biological Sciences at YSU stated, "Each of the 30 strains of bacteria provided by the CDC has demonstrated resistance to a wide variety of antibiotic treatments. The fact that we have been able to eliminate several, individually and in combination is a tremendous step forward. There is still much work to do to test the remaining strains of E. coli and the 30 strains of Candida auris fungus, but we are confident that our success will continue."
Dr. Sturrus, Chair and Professor, Physics, Astronomy Geology and Earth Science Department added, "Each experiment we run builds our knowledge base and uncovers new opportunities for improving the process, optimizing the experimental conditions, and bringing us another step closer to a commercial implementation of the technology."
William A. Hartman, Halberd's Chairman, President & CEO commented, "The ability to eradicate antibiotic resistant bacteria can have an astounding impact on healthcare. It could enable quicker treatments; shorter or eliminated hospitalizations; and reduced suffering and mortality. Most importantly, the eradication of dangerous antibiotic resistant bacteria and fungi takes place outside the body without the use of antibiotics.
"We plan to continue our accelerated eradication of all of the antibiotic resistant bacteria and fungi provided by the CDC and present our findings to the CDC and other government agencies at the appropriate time."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form
NEWS
Halberd Demonstrates Simultaneous Eradication of Multiple Strains of CDC Provided Antibiotic Resistant Bacteria
Killed 99.5% of a mixture of four strains of E. coli bacteria in buffer solution in vitro
JACKSON CENTER, PA / ACCESSWIRE / February 21, 2023 / Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to simultaneously eradicate multiple strains of antibiotic resistant E. coli provided by the CDC in under 10 minutes. Halberd's patented extracorporeal process and patent-pending laser eradication method in conjunction with metallic nanoparticles eliminated 99.5% of the bacteria from the sample.
Dr. Cooper, Professor, Department of Chemical and Biological Sciences at YSU stated, "Each of the 30 strains of bacteria provided by the CDC has demonstrated resistance to a wide variety of antibiotic treatments. The fact that we have been able to eliminate several, individually and in combination is a tremendous step forward. There is still much work to do to test the remaining strains of E. coli and the 30 strains of Candida auris fungus, but we are confident that our success will continue."
Dr. Sturrus, Chair and Professor, Physics, Astronomy Geology and Earth Science Department added, "Each experiment we run builds our knowledge base and uncovers new opportunities for improving the process, optimizing the experimental conditions, and bringing us another step closer to a commercial implementation of the technology."
William A. Hartman, Halberd's Chairman, President & CEO commented, "The ability to eradicate antibiotic resistant bacteria can have an astounding impact on healthcare. It could enable quicker treatments; shorter or eliminated hospitalizations; and reduced suffering and mortality. Most importantly, the eradication of dangerous antibiotic resistant bacteria and fungi takes place outside the body without the use of antibiotics.
"We plan to continue our accelerated eradication of all of the antibiotic resistant bacteria and fungi provided by the CDC and present our findings to the CDC and other government agencies at the appropriate time."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form
Member Level
Re: None
Thursday, February 16, 2023 12:51:47 PM
Post#
25491
of 25491
Halberd Corporation Announces Breakthrough in Candida auris Treatment
Press Release | 02/13/2023
Halberd Demonstrates Eradication of Candida Auris Fungus in as little as 5 minutes.
JACKSON CENTER, PA / ACCESSWIRE / February 13, 2023 / Halberd Corporation (OTC PINK:HALB) a leading provider of innovative healthcare solutions, is proud to announce a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic resistant infectious pathogens sent by the CDC (Centers for Disease Control and Prevention) to Youngstown State University (YSU) for testing. With its scientific partner, Halberd has developed a novel, extracorporeal method of successfully eradicating the multidrug-resistant pathogen using a tuned laser in conjunction with metallic nanoparticles conjugated to a patent-pending non-neutralizing, high-affinity antibody. Halberd previously demonstrated its patent-pending extracorporeal laser eradication by successfully eliminating Escherichia coli and antibiotic resistant strains of Gram-Negative bacteria.
Candida auris is a serious and growing public health threat. It is a multidrug-resistant fungal pathogen that can cause serious infections and is associated with high mortality rates, particularly in immunocompromised patients.
See CBS News report:
"Halberd's innovative approach offers a highly effective solution for treating Candida auris infections and could help to reduce the spread of this pathogen in healthcare settings," stated Dr. Cooper, Professor, Department of Chemical and Biological Sciences at Youngstown State University. "This approach potentially offers a highly effective solution for treating this serious health concern, and we are committed to bring this treatment to patients in need."
William A. Hartman, Halberd's Chairman, President & CEO commented, "An effective treatment of Candida auris would help to address the growing public health threat posed by multidrug-resistant pathogens and the increasing frequency of fungal infections. Halberd's patented breakthrough technology has shown potentially universal capacity to eradicate pathogens. In particular, our patent protected methodologies successfully eradicated in vitro viruses (SARS-CoV-2), inflammatory cytokines, excitatory neurotransmitters (glutamate), antibiotic-resistant bacteria, and now deadly Candida auris fungus. Halberd's patent protected technologies are designed to have a major impact on medical treatments worldwide and lead to improved patient outcomes, fewer deaths, greater longevity and reduced healthcare costs. Halberd's process is effective in minutes, NOT lengthy treatment protocols with potentially harmful and too often ineffectual antibiotics."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
0
Member Level
Re: None
Thursday, February 16, 2023 12:51:47 PM
Post#
25491
of 25491
Halberd Corporation Announces Breakthrough in Candida auris Treatment
Press Release | 02/13/2023
Halberd Demonstrates Eradication of Candida Auris Fungus in as little as 5 minutes.
JACKSON CENTER, PA / ACCESSWIRE / February 13, 2023 / Halberd Corporation (OTC PINK:HALB) a leading provider of innovative healthcare solutions, is proud to announce a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic resistant infectious pathogens sent by the CDC (Centers for Disease Control and Prevention) to Youngstown State University (YSU) for testing. With its scientific partner, Halberd has developed a novel, extracorporeal method of successfully eradicating the multidrug-resistant pathogen using a tuned laser in conjunction with metallic nanoparticles conjugated to a patent-pending non-neutralizing, high-affinity antibody. Halberd previously demonstrated its patent-pending extracorporeal laser eradication by successfully eliminating Escherichia coli and antibiotic resistant strains of Gram-Negative bacteria.
Candida auris is a serious and growing public health threat. It is a multidrug-resistant fungal pathogen that can cause serious infections and is associated with high mortality rates, particularly in immunocompromised patients.
See CBS News report:
"Halberd's innovative approach offers a highly effective solution for treating Candida auris infections and could help to reduce the spread of this pathogen in healthcare settings," stated Dr. Cooper, Professor, Department of Chemical and Biological Sciences at Youngstown State University. "This approach potentially offers a highly effective solution for treating this serious health concern, and we are committed to bring this treatment to patients in need."
William A. Hartman, Halberd's Chairman, President & CEO commented, "An effective treatment of Candida auris would help to address the growing public health threat posed by multidrug-resistant pathogens and the increasing frequency of fungal infections. Halberd's patented breakthrough technology has shown potentially universal capacity to eradicate pathogens. In particular, our patent protected methodologies successfully eradicated in vitro viruses (SARS-CoV-2), inflammatory cytokines, excitatory neurotransmitters (glutamate), antibiotic-resistant bacteria, and now deadly Candida auris fungus. Halberd's patent protected technologies are designed to have a major impact on medical treatments worldwide and lead to improved patient outcomes, fewer deaths, greater longevity and reduced healthcare costs. Halberd's process is effective in minutes, NOT lengthy treatment protocols with potentially harmful and too often ineffectual antibiotics."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
0
Member Level
Re: None
Thursday, February 16, 2023 12:51:47 PM
Post#
25491
of 25491
Halberd Corporation Announces Breakthrough in Candida auris Treatment
Press Release | 02/13/2023
Halberd Demonstrates Eradication of Candida Auris Fungus in as little as 5 minutes.
JACKSON CENTER, PA / ACCESSWIRE / February 13, 2023 / Halberd Corporation (OTC PINK:HALB) a leading provider of innovative healthcare solutions, is proud to announce a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic resistant infectious pathogens sent by the CDC (Centers for Disease Control and Prevention) to Youngstown State University (YSU) for testing. With its scientific partner, Halberd has developed a novel, extracorporeal method of successfully eradicating the multidrug-resistant pathogen using a tuned laser in conjunction with metallic nanoparticles conjugated to a patent-pending non-neutralizing, high-affinity antibody. Halberd previously demonstrated its patent-pending extracorporeal laser eradication by successfully eliminating Escherichia coli and antibiotic resistant strains of Gram-Negative bacteria.
Candida auris is a serious and growing public health threat. It is a multidrug-resistant fungal pathogen that can cause serious infections and is associated with high mortality rates, particularly in immunocompromised patients.
See CBS News report:
"Halberd's innovative approach offers a highly effective solution for treating Candida auris infections and could help to reduce the spread of this pathogen in healthcare settings," stated Dr. Cooper, Professor, Department of Chemical and Biological Sciences at Youngstown State University. "This approach potentially offers a highly effective solution for treating this serious health concern, and we are committed to bring this treatment to patients in need."
William A. Hartman, Halberd's Chairman, President & CEO commented, "An effective treatment of Candida auris would help to address the growing public health threat posed by multidrug-resistant pathogens and the increasing frequency of fungal infections. Halberd's patented breakthrough technology has shown potentially universal capacity to eradicate pathogens. In particular, our patent protected methodologies successfully eradicated in vitro viruses (SARS-CoV-2), inflammatory cytokines, excitatory neurotransmitters (glutamate), antibiotic-resistant bacteria, and now deadly Candida auris fungus. Halberd's patent protected technologies are designed to have a major impact on medical treatments worldwide and lead to improved patient outcomes, fewer deaths, greater longevity and reduced healthcare costs. Halberd's process is effective in minutes, NOT lengthy treatment protocols with potentially harmful and too often ineffectual antibiotics."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
0